The fight against COVID19
23.85k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The fight against COVID19 | +0.28% | - | - | - |
| ^GSPC | +0.63% | +3.88% | +33.79% | +6192.00% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 161.602 | +0.14 | +0.09% | 11:17 am GMT-4 | 1.41M | 6.55M | 389.01B |
| ABBV | AbbVie Inc. | 195.17 | +0.98 | +0.50% | 11:17 am GMT-4 | 786.70k | 4.71M | 344.74B |
| PFE | Pfizer Inc. | 29.0176 | -0.14 | -0.49% | 11:17 am GMT-4 | 6.84M | 31.95M | 164.43B |
| SNY | Sanofi | 55.4 | +0.44 | +0.80% | 11:17 am GMT-4 | 526.14k | 1.80M | 139.09B |
| REGN | Regeneron Pharmaceuticals, Inc. | 1016.19 | +0.52 | +0.05% | 11:15 am GMT-4 | 77.51k | 536.85k | 112.02B |
| GILD | Gilead Sciences, Inc. | 84.71 | -0.24 | -0.28% | 11:17 am GMT-4 | 697.59k | 6.44M | 105.46B |
| GSK | GSK plc | 38.97 | +0.14 | +0.36% | 11:17 am GMT-4 | 2.33M | 4.00M | 80.51B |
| TAK | Takeda Pharmaceutical Company Limited | 14.282 | -0.02 | -0.13% | 11:17 am GMT-4 | 329.46k | 2.26M | 45.34B |
| BNTX | BioNTech SE | 120.835 | +0.32 | +0.26% | 11:16 am GMT-4 | 116.17k | 955.89k | 28.73B |
| MRNA | Moderna, Inc. | 58.31 | +0.02 | +0.03% | 11:17 am GMT-4 | 1.02M | 4.77M | 22.41B |
| NVAX | Novavax, Inc. | 12.79 | +0.26 | +2.08% | 11:17 am GMT-4 | 3.06M | 6.72M | 2.05B |
| VIR | Vir Biotechnology, Inc. | 7.75 | +0.16 | +2.11% | 11:17 am GMT-4 | 162.89k | 774.51k | 1.06B |
| INO | Inovio Pharmaceuticals, Inc. | 5.7 | -0.05 | -0.87% | 11:14 am GMT-4 | 102.02k | 319.57k | 148.00M |
BenzingaMore Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s (NYSE: JNJ) Stelara (ustekinumab)) in adults with moderately to severely active Crohn’s disease. The data showed that more patients achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075). Also Read: Novo Nordisk, Eli Lilly Cou
Investor's Business DailyWhy Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.
BenzingaHow Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Brookfield Infrastructure Partners, Invitation Homes and Gilead Sciences have rewarded their shareholders for several decades ...
